Mamitaro Ohtsuki

Tochigi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 198 publications

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

Journal: The Journal of dermatology

Published: April 28, 2026

Generalized pustular psoriasis exhibits highly variable flare intervals with no identifiable baseline predictors: A retrospective case series of 40 patients.

Generalized pustular psoriasis exhibits highly variable flare intervals with no identifiable baseline predictors: A retrospective case series of 40 patients.

Journal: JAAD international

Published: April 24, 2026

Extramammary Paget's disease in situ of the scrotum and penis with cervical lymph node metastasis of unknown origin.

Extramammary Paget's disease in situ of the scrotum and penis with cervical lymph node metastasis of unknown origin.

Journal: European journal of dermatology : EJD

Published: September 18, 2025

Prospective, Open-Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics.

Prospective, Open-Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics.

Journal: The Journal of dermatology

Published: August 05, 2025

Refractory Psoriatic Lesions in Japanese Patients With Biologics.

Refractory Psoriatic Lesions in Japanese Patients With Biologics.

Journal: The Journal of dermatology

Published: June 27, 2025

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.

Journal: American journal of clinical dermatology

Published: June 23, 2025

Acid ceramidase overactivity drives ceramide loss, leading to atopic dry skin and Th2-skewed immune polarization.

Acid ceramidase overactivity drives ceramide loss, leading to atopic dry skin and Th2-skewed immune polarization.

Journal: The Journal of pathology

Published: May 23, 2025

Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.

Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.

Journal: Dermatology and therapy

Published: May 06, 2025

Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics.

Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics.

Journal: The Journal of dermatology

Published: April 03, 2025

Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study.

Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study.

Journal: The Journal of dermatology

Published: February 14, 2025

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 Trial.

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 Trial.

Journal: The Journal of dermatology

Published: January 10, 2025

Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.

Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.

Journal: Dermatology and therapy

Published: December 10, 2024

Showing 1-12 of 198

Last Updated: 09/26/2026